STOCK TITAN

Aclaris Therapeutics (ACRS) Stock News

ACRS NASDAQ

Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.

Rhea-AI Summary

Aclaris Therapeutics (ACRS) initiated the Phase 2b ALPHA trial of modzatinib in moderate-to-severe lichen planus, starting with an oral erosive cohort. The randomized, double-blind, placebo-controlled study will assess two dose levels in approximately 100 participants whose biopsy-proven disease is inadequately controlled with topical therapies. It includes oral erosive, cutaneous and scalp disease cohorts, with primary disease-activity endpoints at Week 16 for the first two and Week 24 for the scalp cohort. Modzatinib has FDA Fast Track Designation for moderate-to-severe lichen planus.

Aclaris expects oral-cohort top-line results in the second half of 2027. It also expects an ATI-9494 investigational new drug application this quarter and trial initiation in the first quarter of 2027. The company intends to start an ATI-052 Phase 2b trial in eosinophilic esophagitis in the first quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Aclaris Therapeutics (ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis missed its primary and secondary endpoints. The primary endpoint measured the percentage change from baseline in Eczema Area and Severity Index score at week 24. Biological measurements showed TSLP target engagement and reductions in biomarkers linked to immune activation. Bosakitug was generally well tolerated.

Aclaris said its development priorities remain oral kinase inhibitors and the bispecific antibody ATI-052. It has initiated a Phase 2b trial of modzatinib in lichen planus and completed studies supporting an investigational new drug application for ATI-9494. The company expects to file that application this quarter and intends to initiate a Phase 2b trial of ATI-052 in eosinophilic esophagitis in the first quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Aclaris Therapeutics (ACRS) will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 16 in London.

CEO Dr. Neal Walker and other senior leadership members will join the discussion at 10:30 AM GMT (5:30 AM ET). A live and archived webcast will be accessible through the Events page at www.aclaristx.com, with the recording available for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
none
Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) reported a third-quarter net loss of $18.510 million alongside clinical results and upcoming development milestones. Revenue fell to $1.481 million from $3.299 million a year earlier; net loss was $14.614 million in the prior-year quarter.

ATI-052 Phase 1b results included a 45% placebo-adjusted mean improvement in eczema severity at week 8 and a 200 ml placebo-adjusted lung-function improvement in asthma at day 15. Aclaris plans Phase 2b development initially in eosinophilic esophagitis in early 2027. Bosakitug Phase 2 results, modzatinib Phase 2b initiation and an ATI-9494 investigational-drug application are expected in fourth-quarter 2026.

Cash and investments totaled $204.607 million at September 30. An October offering raised $50.0 million gross; including its net proceeds, Aclaris expects funding through first-half 2029, excluding potential business development transactions or additional financing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.90%
Tags
-
Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) priced an underwritten offering expected to raise approximately $50.0 million in gross proceeds.

The offering comprises 7,785,714 common shares at $3.50 each and pre-funded warrants to purchase 6,500,000 shares at $3.49999 each, with a $0.00001 exercise price per share. All securities will be sold by Aclaris. Participants include TCGX, RA Capital Management, Invus and a large mutual fund. Aclaris expects closing on October 28, 2026, subject to customary closing conditions. Gross proceeds exclude underwriting discounts, commissions and other offering expenses payable by Aclaris.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Summary

Aclaris Therapeutics (ACRS) reported Phase 1b results for ATI-052 in atopic dermatitis and asthma, with both trials meeting their primary safety objective. The trials enrolled 14 and 16 patients, respectively. No Grade 3 or 4 treatment-emergent adverse events, adverse-event discontinuations or conjunctivitis were observed.

In atopic dermatitis, the day-57 mean improvement in the Eczema Area and Severity Index was 45% placebo-adjusted; itch improvement was 43% placebo-adjusted. In asthma, a single dose reduced exhaled nitric oxide, an airway inflammation marker, by 59% at day 15 versus 15% with placebo. Mean improvement in one-second exhaled air volume was 200 ml, both absolute and placebo-adjusted, at day 15. Aclaris intends to prioritize a Phase 2b trial in eosinophilic esophagitis early next year and update plans for a potential additional indication in the near term.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
Rhea-AI Summary

Aclaris Therapeutics (ACRS) will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, at 2:45 PM ET.

The session will feature Chief Executive Officer Dr. Neal Walker. A live and archived webcast will be available on the Events page of the Aclaris website for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
none
-
Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) announced that the U.S. FDA has granted Fast Track Designation for its investigational therapy modzatinib (ATI-2138) for moderate to severe lichen planus (LP), including oral erosive LP, cutaneous LP, and lichen planopilaris.

According to Aclaris, Fast Track status enables more frequent FDA interactions, the possibility of rolling New Drug Application review, and potential eligibility for Priority Review if criteria are met. The company expects to initiate a phased, multi-part Phase 2b LP trial in the fourth quarter of 2026 as it advances its immuno-inflammatory pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
-
Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) reported second quarter 2026 net loss of $21.5 million versus $15.4 million a year earlier on total revenue of $1.6 million versus $1.8 million. R&D rose to $18.1 million, driven mainly by ATI-052 and ATI-9494 development, while G&A increased to $6.0 million.

Cash, cash equivalents and marketable securities were $170.6 million at June 30, 2026, up from $151.4 million at year-end 2025. After quarter-end, Aclaris raised $40.2 million gross via sale of 7.3 million shares under its ATM, and now expects its cash to fund operations through end of 2028. Clinically, full Phase 1a SAD/MAD data for bispecific antibody ATI-052 showed a favorable safety profile and PK/PD supporting potential quarterly dosing, and timelines were reaffirmed for 2026 readouts from two Phase 1b POC trials of ATI-052 and a Phase 2 trial of anti-TSLP antibody bosakitug (ATI-045).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
Rhea-AI Summary

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.

The event is scheduled for June 4, 2026 at 2:00 PM ET, with a live and archived webcast available on Aclaris’ website for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
none

FAQ

What is the current stock price of Aclaris Therapeutics (ACRS)?

Aclaris Therapeutics (ACRS) last closed at $3.92.

What is the market cap of Aclaris Therapeutics (ACRS)?

The market cap of Aclaris Therapeutics (ACRS) is approximately $621.8M.